Annual Report 2024

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2024 102 The United Laboratories International Holdings Limited Annual Report 2024 19. GOODWILL RMB’000 COST At 1 January 2023, 31 December 2023 and 2024 3,031 Goodwill has been allocated to two individual cash-generating units, including one subsidiary which operates in the Bulk medicine segment and one subsidiary which operates in the Finished products segment. The carrying amounts of goodwill at the end of the reporting period allocated to these units are as follows: 2024 2023 RMB’000 RMB’000 Bulk medicine 774 774 Finished products 2,257 2,257 3,031 3,031 The directors of the Company are of the opinion that no impairment (2023: no impairment) is recognised after performing the impairment assessment for the year ended 31 December 2024.